Henan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1977-01-01

Employees: -

Market Cap: -

Website: http://www.anti-cancer.com.cn

Clinical Trials

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Phase 1

Conditions: B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: CART-19

First Posted Date: 2017-04-05

Last Posted Date: 2017-04-05

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT03101709

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer

Phase 2

Terminated

Conditions: Advanced Cancer

Interventions: Biological: Cytokine-induced Killer Cells
Drug: Tegafur-Gimeracil-Oteracil Potassium

First Posted Date: 2016-12-26

Last Posted Date: 2020-04-02

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 13

Registration Number: NCT03002831

Locations: 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

Phase 1

Conditions: B-cell Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: CART-19 cells

First Posted Date: 2016-10-05

Last Posted Date: 2017-12-29

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT02924753

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Phase 2

Conditions: Lung Adenocarcinoma

Interventions: Drug: Icotinib
Drug: Pemetrexed/Carboplatin

First Posted Date: 2016-04-14

Last Posted Date: 2020-07-01

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT02737774

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Phase 2

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Chidamide
Drug: Vinorelbine
Drug: Liposomal Doxorubicin or mitoxantrone
Drug: Dexamethasone
Drug: Thalidomide

First Posted Date: 2016-04-11

Last Posted Date: 2020-04-01

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT02733380

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

Phase 2

Terminated

Conditions: Lung Adenocarcinoma

Interventions: Biological: CIK
Drug: chemotherapy

First Posted Date: 2015-12-03

Last Posted Date: 2021-05-12

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 280

Registration Number: NCT02621333

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China

Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma

Phase 3

Completed

Conditions: Esophageal Neoplasm

Interventions: Drug: cisplatin and paclitaxel

First Posted Date: 2015-03-24

Last Posted Date: 2022-10-05

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 528

Registration Number: NCT02395705

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Fujian Medical University Union Hospital, FuZhou, Fujian, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 6 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy